What is Zacks Research’s Forecast for ONCY Q1 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Research analysts at Zacks Research issued their Q1 2026 earnings estimates for shares of Oncolytics Biotech in a research report issued on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($0.06) per share for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. Zacks Research also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.

Several other equities research analysts also recently weighed in on ONCY. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Friday, March 27th. Wall Street Zen raised shares of Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a report on Saturday, April 4th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Oncolytics Biotech has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Oncolytics Biotech Stock Performance

ONCY opened at $1.04 on Thursday. The company has a 50-day moving average of $0.97 and a 200-day moving average of $1.05. The company has a market capitalization of $120.78 million, a P/E ratio of -3.59 and a beta of 0.98. Oncolytics Biotech has a 1-year low of $0.33 and a 1-year high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last released its earnings results on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ONCY. Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech in the 3rd quarter valued at about $535,000. Scientech Research LLC acquired a new position in Oncolytics Biotech during the 3rd quarter valued at about $25,000. Ground Swell Capital LLC acquired a new position in Oncolytics Biotech during the 4th quarter valued at about $30,000. CIBC Private Wealth Group LLC acquired a new position in Oncolytics Biotech during the 4th quarter valued at about $44,000. Finally, Tocqueville Asset Management L.P. acquired a new position in Oncolytics Biotech during the 4th quarter valued at about $63,000. 6.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Oncolytics Biotech

In other Oncolytics Biotech news, Director Wayne Pisano purchased 30,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The stock was acquired at an average cost of $0.84 per share, with a total value of $25,200.00. Following the acquisition, the director owned 492,414 shares of the company’s stock, valued at approximately $413,627.76. This represents a 6.49% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bernd R. Seizinger purchased 100,000 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was acquired at an average cost of $1.04 per share, with a total value of $104,000.00. Following the completion of the acquisition, the director directly owned 466,991 shares in the company, valued at approximately $485,670.64. This trade represents a 27.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 404,282 shares of company stock valued at $363,232. Corporate insiders own 0.10% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.